WO1996029409A3 - Rage tumor rejection antigens - Google Patents

Rage tumor rejection antigens Download PDF

Info

Publication number
WO1996029409A3
WO1996029409A3 PCT/US1996/004037 US9604037W WO9629409A3 WO 1996029409 A3 WO1996029409 A3 WO 1996029409A3 US 9604037 W US9604037 W US 9604037W WO 9629409 A3 WO9629409 A3 WO 9629409A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor rejection
rejection antigen
rage
rejection antigens
rage tumor
Prior art date
Application number
PCT/US1996/004037
Other languages
French (fr)
Other versions
WO1996029409A2 (en
Inventor
Beatrice Gaugler
Den Eynde Benoit Ven
Peter Schrier
Nathalie Brouwenstijn
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/530,569 external-priority patent/US5939526A/en
Application filed by Ludwig Inst Cancer Res, Univ Leiden filed Critical Ludwig Inst Cancer Res
Priority to NZ306122A priority Critical patent/NZ306122A/en
Priority to JP8528658A priority patent/JPH11506904A/en
Priority to EP96911399A priority patent/EP0815229A2/en
Priority to AU54298/96A priority patent/AU705768B2/en
Publication of WO1996029409A2 publication Critical patent/WO1996029409A2/en
Publication of WO1996029409A3 publication Critical patent/WO1996029409A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.
PCT/US1996/004037 1995-03-21 1996-03-21 Rage tumor rejection antigens WO1996029409A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
NZ306122A NZ306122A (en) 1995-03-21 1996-03-21 Rage tumour rejection antigen precursors, diagnosis and treatment thereby
JP8528658A JPH11506904A (en) 1995-03-21 1996-03-21 RAGE tumor rejection antigen
EP96911399A EP0815229A2 (en) 1995-03-21 1996-03-21 Rage tumor rejection antigens
AU54298/96A AU705768B2 (en) 1995-03-21 1996-03-21 Rage tumor rejection antigens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40801595A 1995-03-21 1995-03-21
US08/408,015 1995-03-21
US08/530,569 1995-09-20
US08/530,569 US5939526A (en) 1995-03-21 1995-09-20 Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof

Publications (2)

Publication Number Publication Date
WO1996029409A2 WO1996029409A2 (en) 1996-09-26
WO1996029409A3 true WO1996029409A3 (en) 1996-11-07

Family

ID=27020105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004037 WO1996029409A2 (en) 1995-03-21 1996-03-21 Rage tumor rejection antigens

Country Status (6)

Country Link
EP (1) EP0815229A2 (en)
JP (1) JPH11506904A (en)
AU (1) AU705768B2 (en)
CA (1) CA2211448A1 (en)
NZ (1) NZ306122A (en)
WO (1) WO1996029409A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050551A1 (en) * 1997-05-05 1998-11-12 Incyte Pharmaceuticals, Inc. Rage1-like protein
AU8571598A (en) * 1997-07-17 1999-02-10 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
AU3900399A (en) * 1998-05-13 1999-11-29 Ludwig Institute For Cancer Research Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
CN1367830A (en) * 1998-10-05 2002-09-04 路德维哥癌症研究院 Cancer associated antigens and uses therefor
WO2000020586A2 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
US20110311448A1 (en) * 2007-11-02 2011-12-22 Ann Marie Schmidt Antibody to rage and uses for in vivo imaging or for targeting therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005304A1 (en) * 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005304A1 (en) * 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBL DATABASE, Accession number M91400 Sequence reference HSRTPGEU;21 July 1992 Compare with nucleotides 1079-1309 of SEQ. ID. NO. 1 *
T.BOON ET AL.: "Genes coding for tumor-specific rejection antigens", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 59 The Molecular Genetics of Cancer, 1994, pages 617 - 622, XP000601971 *

Also Published As

Publication number Publication date
AU705768B2 (en) 1999-06-03
EP0815229A2 (en) 1998-01-07
CA2211448A1 (en) 1996-09-26
JPH11506904A (en) 1999-06-22
WO1996029409A2 (en) 1996-09-26
AU5429896A (en) 1996-10-08
NZ306122A (en) 1999-06-29

Similar Documents

Publication Publication Date Title
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
CA2167692A1 (en) Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
CA2103059A1 (en) Method for making humanized antibodies
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
NO963589L (en) Description of cancer states by MAGE gene expression
HUT75524A (en) Syntetic excitatory amino acids, pharmaceutical compns. contg. them, process for preparing the said compds. and their intermediates
WO1999020756A3 (en) Human toll homologues
CA2068222A1 (en) Monoclonal antibodies
HUP9902605A3 (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
HUP9702359A3 (en) Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody
WO1996029409A3 (en) Rage tumor rejection antigens
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
EP0253325A3 (en) Oncogene-related peptides
CA2013544A1 (en) Retinoblastoma gene product antibodies and uses therefor
MX9601930A (en) Anti-idiotypic antibodies which induce an immune response against growth factor receptor.
WO1997035015A3 (en) Tyrosine-phosphatase-related protein
EP0780472A3 (en) Stress proteins
AU7128098A (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
WO1999063093A3 (en) Basb027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
AU3637195A (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
WO1997005253A3 (en) Transketolase-related protein
GB9804529D0 (en) Method for the detection of antigens or antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192650.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP NO NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 306122

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2211448

Country of ref document: CA

Ref document number: 2211448

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1996 528658

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996911399

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996911399

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996911399

Country of ref document: EP